Picture of couple

The South Plains Oncology Consortium (SPOC) is a regional consortium devoted to conducting early phase oncology trials and translational cancer research.

A major goal of SPOC is to improve access for new anti-cancer drugs to patients in West Texas and the surrounding region.

Latest News

  • July 2016
    A video describing SPOC-2013-001, Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-SorbTM (LXS) Oral Powder Plus Ketoconazole Plus Vincristine in Patients with Recurrent or Resistant Neuroblastoma (IND #: 68,254), is now available. It can be viewed here on our website.
    read more »
  • April 2016
    The FDA has now cleared the formulated clinical safingol for use in the SPOC Phase I study (SPOC 2010-02). This phase I study will be open to patient accrual in summer of 2016.
    read more »

Related Links
Texas Cancer Cell RepositoryTexas Cancer Research Biobank

© South Plains Oncology Consortium (2008-2019)